Acurx Historical Balance Sheet

ACXP Stock

USD 0.41 0.01 2.38%

Trend analysis of Acurx Pharmaceuticals LLC balance sheet accounts such as Other Current Liab of 3.4 B, Total Current Liabilities of 3.4 B or Total Stockholder Equity of 645.9 M provides information on Acurx Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Acurx Pharmaceuticals LLC to its prevalent stockholders. By breaking down trends over time using Acurx Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Acurx Pharmaceuticals LLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Acurx Pharmaceuticals LLC is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acurx Pharmaceuticals LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

About Acurx Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Acurx Pharmaceuticals LLC at a specified time, usually calculated after every quarter, six months, or one year. Acurx Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Acurx Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Acurx currently owns. An asset can also be divided into two categories, current and non-current.

Acurx Pharmaceuticals Balance Sheet Chart

At this time, Acurx Pharmaceuticals' Other Current Assets are relatively stable compared to the past year. As of 03/29/2025, Other Stockholder Equity is likely to grow to about 71.3 B, though Retained Earnings are likely to grow to (64 B).

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Total Assets

Total assets refers to the total amount of Acurx Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Acurx Pharmaceuticals LLC books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Acurx Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Acurx Pharmaceuticals LLC are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Acurx Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Acurx Pharmaceuticals LLC current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acurx Pharmaceuticals LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	2.0M	3.0M	3.2B	3.4B
Total Assets	9.4M	7.7M	3.9B	4.1B

Other Current Liab Total Assets

Acurx Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Short Long Term Debt Total	Long Term Debt	Short Long Term Debt	Short Term Debt	Other Assets	Net Receivables
Total Assets		1.0	1.0	1.0	0.42	0.03	-1.0	-0.12	0.15	0.15	0.49	0.83	0.25	1.0	1.0	-0.14	0.15	-0.54	-0.2	-0.54	-0.95	-0.95	-0.95	-0.95	-0.51	-0.98
Other Current Liab	1.0		1.0	1.0	0.42	0.03	-1.0	-0.13	0.15	0.15	0.49	0.83	0.25	1.0	1.0	-0.14	0.15	-0.53	-0.2	-0.53	-0.95	-0.95	-0.95	-0.95	-0.5	-0.98
Total Current Liabilities	1.0	1.0		1.0	0.42	0.03	-1.0	-0.13	0.15	0.15	0.49	0.83	0.25	1.0	1.0	-0.14	0.15	-0.53	-0.2	-0.53	-0.95	-0.95	-0.95	-0.95	-0.5	-0.98
Total Stockholder Equity	1.0	1.0	1.0		0.44	0.02	-1.0	-0.11	0.16	0.16	0.5	0.83	0.27	1.0	1.0	-0.13	0.16	-0.54	-0.19	-0.54	-0.95	-0.95	-0.95	-0.95	-0.51	-0.98
Net Tangible Assets	0.42	0.42	0.42	0.44		-0.88	-0.43	0.57	0.91	0.91	0.87	0.59	0.89	0.42	0.42	0.44	0.91	-0.86	0.78	-0.86	-0.37	-0.37	-0.37	-0.37	-0.55	-0.44
Net Debt	0.03	0.03	0.03	0.02	-0.88		-0.03	-0.65	-0.97	-0.97	-0.65	-0.17	-0.92	0.03	0.03	-0.5	-0.97	0.71	-0.97	0.71	-0.03	-0.03	-0.03	-0.03	0.41	-0.04
Retained Earnings	-1.0	-1.0	-1.0	-1.0	-0.43	-0.03		0.13	-0.14	-0.14	-0.5	-0.85	-0.25	-1.0	-1.0	0.14	-0.14	0.53	0.2	0.53	0.93	0.93	0.93	0.93	0.5	0.99
Accounts Payable	-0.12	-0.13	-0.13	-0.11	0.57	-0.65	0.13		0.62	0.62	0.6	-0.09	0.58	-0.13	-0.13	0.1	0.61	-0.1	0.76	-0.1	0.12	0.12	0.12	0.12	-0.11	0.12
Cash	0.15	0.15	0.15	0.16	0.91	-0.97	-0.14	0.62		1.0	0.68	0.25	0.95	0.15	0.15	0.46	1.0	-0.78	0.91	-0.78	-0.2	-0.2	-0.2	-0.2	-0.49	-0.11
Cash And Short Term Investments	0.15	0.15	0.15	0.16	0.91	-0.97	-0.14	0.62	1.0		0.68	0.25	0.95	0.15	0.15	0.46	1.0	-0.78	0.91	-0.78	-0.2	-0.2	-0.2	-0.2	-0.49	-0.11
Common Stock Total Equity	0.49	0.49	0.49	0.5	0.87	-0.65	-0.5	0.6	0.68	0.68		0.71	0.68	0.49	0.49	0.42	0.68	-0.67	0.57	-0.67	-0.39	-0.39	-0.39	-0.39	-0.62	-0.53
Common Stock Shares Outstanding	0.83	0.83	0.83	0.83	0.59	-0.17	-0.85	-0.09	0.25	0.25	0.71		0.31	0.83	0.83	0.27	0.25	-0.69	-0.01	-0.69	-0.67	-0.67	-0.67	-0.67	-0.56	-0.89
Other Current Assets	0.25	0.25	0.25	0.27	0.89	-0.92	-0.25	0.58	0.95	0.95	0.68	0.31		0.25	0.25	0.23	0.95	-0.8	0.85	-0.8	-0.27	-0.27	-0.27	-0.27	-0.65	-0.23
Other Stockholder Equity	1.0	1.0	1.0	1.0	0.42	0.03	-1.0	-0.13	0.15	0.15	0.49	0.83	0.25		1.0	-0.14	0.15	-0.54	-0.2	-0.54	-0.95	-0.95	-0.95	-0.95	-0.51	-0.98
Total Liab	1.0	1.0	1.0	1.0	0.42	0.03	-1.0	-0.13	0.15	0.15	0.49	0.83	0.25	1.0		-0.14	0.15	-0.53	-0.2	-0.53	-0.95	-0.95	-0.95	-0.95	-0.5	-0.98
Net Invested Capital	-0.14	-0.14	-0.14	-0.13	0.44	-0.5	0.14	0.1	0.46	0.46	0.42	0.27	0.23	-0.14	-0.14		0.46	-0.46	0.41	-0.46	0.13	0.13	0.13	0.13	-0.12	0.13
Total Current Assets	0.15	0.15	0.15	0.16	0.91	-0.97	-0.14	0.61	1.0	1.0	0.68	0.25	0.95	0.15	0.15	0.46		-0.78	0.91	-0.78	-0.2	-0.2	-0.2	-0.2	-0.5	-0.11
Capital Stock	-0.54	-0.53	-0.53	-0.54	-0.86	0.71	0.53	-0.1	-0.78	-0.78	-0.67	-0.69	-0.8	-0.54	-0.53	-0.46	-0.78		-0.53	1.0	0.5	0.5	0.5	0.5	0.7	0.53
Net Working Capital	-0.2	-0.2	-0.2	-0.19	0.78	-0.97	0.2	0.76	0.91	0.91	0.57	-0.01	0.85	-0.2	-0.2	0.41	0.91	-0.53		-0.53	0.19	0.19	0.19	0.19	-0.27	0.2
Common Stock	-0.54	-0.53	-0.53	-0.54	-0.86	0.71	0.53	-0.1	-0.78	-0.78	-0.67	-0.69	-0.8	-0.54	-0.53	-0.46	-0.78	1.0	-0.53		0.5	0.5	0.5	0.5	0.7	0.53
Short Long Term Debt Total	-0.95	-0.95	-0.95	-0.95	-0.37	-0.03	0.93	0.12	-0.2	-0.2	-0.39	-0.67	-0.27	-0.95	-0.95	0.13	-0.2	0.5	0.19	0.5		1.0	1.0	1.0	0.49	0.87
Long Term Debt	-0.95	-0.95	-0.95	-0.95	-0.37	-0.03	0.93	0.12	-0.2	-0.2	-0.39	-0.67	-0.27	-0.95	-0.95	0.13	-0.2	0.5	0.19	0.5	1.0		1.0	1.0	0.49	0.87
Short Long Term Debt	-0.95	-0.95	-0.95	-0.95	-0.37	-0.03	0.93	0.12	-0.2	-0.2	-0.39	-0.67	-0.27	-0.95	-0.95	0.13	-0.2	0.5	0.19	0.5	1.0	1.0		1.0	0.49	0.87
Short Term Debt	-0.95	-0.95	-0.95	-0.95	-0.37	-0.03	0.93	0.12	-0.2	-0.2	-0.39	-0.67	-0.27	-0.95	-0.95	0.13	-0.2	0.5	0.19	0.5	1.0	1.0	1.0		0.49	0.87
Other Assets	-0.51	-0.5	-0.5	-0.51	-0.55	0.41	0.5	-0.11	-0.49	-0.49	-0.62	-0.56	-0.65	-0.51	-0.5	-0.12	-0.5	0.7	-0.27	0.7	0.49	0.49	0.49	0.49		0.49
Net Receivables	-0.98	-0.98	-0.98	-0.98	-0.44	-0.04	0.99	0.12	-0.11	-0.11	-0.53	-0.89	-0.23	-0.98	-0.98	0.13	-0.11	0.53	0.2	0.53	0.87	0.87	0.87	0.87	0.49

Click cells to compare fundamentals

Acurx Pharmaceuticals Account Relationship Matchups

Acurx Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	3.2M	13.3M	9.4M	7.7M	3.9B	4.1B
Other Current Liab	455.9K	780.5K	2.0M	3.0M	3.2B	3.4B
Total Current Liabilities	472.6K	843.9K	2.1M	3.0M	3.2B	3.4B
Total Stockholder Equity	2.7M	12.4M	7.3M	4.7M	615.1M	645.9M
Net Debt	(3.1M)	(13.0M)	(9.1M)	(7.5M)	(3.7M)	(3.9M)
Retained Earnings	(13.8M)	(26.5M)	(38.6M)	(53.2M)	(67.3B)	(64.0B)
Cash	3.2M	13.0M	9.1M	7.5M	3.7M	7.1M
Cash And Short Term Investments	3.2M	13.0M	9.1M	7.5M	3.7M	7.1M
Liabilities And Stockholders Equity	3.2M	13.3M	9.4M	7.7M	3.9B	4.1B
Other Current Assets	48.6K	295.3K	265.0K	105.8K	121.6K	167.8K
Other Stockholder Equity	13.8M	38.9M	84.6M	57.9M	67.9B	71.3B
Total Liab	522.4K	843.9K	2.1M	3.0M	3.2B	3.4B
Net Invested Capital	2.8M	12.4M	7.3M	57.9M	615.1K	584.4K
Total Current Assets	3.2M	13.3M	9.4M	7.7M	3.9M	7.3M
Capital Stock	16.5M	10.2K	11.6K	14.5K	17.0K	16.2K
Net Working Capital	2.8M	12.4M	7.3M	4.7M	615.1K	584.4K
Common Stock	16.5M	10.2K	11.6K	14.5K	17.0K	16.2K

Pair Trading with Acurx Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acurx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acurx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Acurx Stock

0.8

CDIOW

Cardio Diagnostics

Pair Corr

Moving against Acurx Stock

0.72	LUCD	Lucid Diagnostics	Pair Corr
0.64	WM	Waste Management	Pair Corr
0.5	GE	GE Aerospace	Pair Corr
0.36	PG	Procter Gamble Sell-off Trend	Pair Corr
0.34	PLX	Protalix Biotherapeutics	Pair Corr

The ability to find closely correlated positions to Acurx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acurx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acurx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acurx Pharmaceuticals LLC to buy it.

The correlation of Acurx Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acurx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acurx Pharmaceuticals LLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Acurx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Acurx Stock Analysis

When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Acurx Historical Balance Sheet

About Acurx Balance Sheet Analysis

Acurx Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Acurx Pharmaceuticals balance sheet Correlations

Acurx Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Acurx Pharmaceuticals balance sheet Accounts

Pair Trading with Acurx Pharmaceuticals

Moving together with Acurx Stock

Moving against Acurx Stock

Additional Tools for Acurx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Liab	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Total Assets
Total Stockholder Equity	+ 1.0	Total Assets
Other Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab

Total Liab	- 1.0	Retained Earnings
Other Stockholder Equity	- 1.0	Retained Earnings
Retained Earnings	- 1.0	Total Stockholder Equity
Retained Earnings	- 1.0	Total Current Liabilities
Retained Earnings	- 1.0	Other Current Liab
Retained Earnings	- 1.0	Total Assets